CJC-1295/Ipamorelin 7.5mg/15mg 10mL Vial

• May increase natural growth hormone release
• May support fat loss
• May aid muscle growth and recovery
• May improve skin health
• May offer anti-aging benefits
• May support joint and bone health
• May enhance sleep quality and recovery

• Dosing: 100mcg CJC-1295 and 200mcg of Ipamorelin
  • Draw 8 units (0.08mL) for each dose 
  • 5x days per week, 2 consecutive days 
  • Administer at night 60+ minutes before bed, on empty stomach

• Duration: 3 months 
• Reconstitute: Add 6mL bacteriostatic water to the 7.5mg/15mg vial of CJC-1295 and Ipamorelin
• Subcutaneous injection

CJC-1295: 

• Pituitary GHRH Receptor Activation:

• CJC-1295 is a synthetic analog of endogenous growth hormone–releasing hormone (GHRH) that binds to GHRH receptors in the anterior pituitary. This interaction stimulates the pulsatile secretion of growth hormone (GH), maintaining physiologic rhythmicity and preserving normal feedback control mechanisms.

• IGF-1 Stimulation and Anabolic Activity:

• By increasing GH output, CJC-1295 enhances hepatic production of insulin-like growth factor-1 (IGF-1). Elevated IGF-1 promotes protein synthesis, cellular repair, and recovery in muscle, bone, and connective tissue. This activity supports lean mass development and tissue regeneration.

• Metabolic Regulation:

• Increased GH and IGF-1 signaling promote lipolysis, improved lipid metabolism, and enhanced mitochondrial activity. These effects collectively support energy balance, fat utilization, and overall metabolic health.

• GH Pulsatility and Physiologic Half-Life:

• The non-DAC form of CJC-1295 exhibits a short half-life (~30 minutes), producing a natural GH pulse that mimics physiologic secretion patterns. This transient activity reduces the risk of receptor desensitization and maintains optimal hormonal balance.

Ipamorelin: 

• Selective Growth Hormone Secretagogue Receptor (GHS-R1a) Activation:
  • Ipamorelin is a highly selective ghrelin mimetic that binds to GHS-R1a receptors on pituitary somatotrophs, stimulating GH release. It increases GH secretion without significantly affecting cortisol, prolactin, or ACTH, resulting in a clean, targeted endocrine response.
• Amplified GH Release and Synergy with GHRH Analogs:
  • When combined with GHRH analogs such as CJC-1295, Ipamorelin acts synergistically through complementary receptor pathways. This dual stimulation enhances both the frequency and amplitude of GH pulses, maximizing anabolic and recovery effects.
• Anabolic and Repair Pathways:
  • Ipamorelin-induced GH secretion promotes IGF-1 synthesis, accelerating tissue repair, muscle recovery, and connective tissue regeneration. This anabolic signaling also supports improved physical performance and cellular rejuvenation.
• Metabolic and Neuroendocrine Benefits:
  • By optimizing GH pulsatility, Ipamorelin supports lipid mobilization, improved insulin sensitivity, and enhanced mitochondrial function. Its influence on GH-related sleep regulation also contributes to restorative sleep quality and overall metabolic homeostasis.

• Disclaimer: For Research Purposes Only – All products on this site are for Research and Development use only. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease. Celia Health is a supplier of research-use chemicals manufactured in a CGMP facility in the US. Celia Health  is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act.